R42-VRP VC Demo Day
August 15th
Hosted by R42 at VRP campus. Drinks/Food by Valley BioSciences.
1:15 - 2:00 Networking
2:00-3:30 R42-VRP deep science pitch day
3:30-5:00 Networking and lab or desk visits.
Format: Companies will do 5 min Pitches presentations followed by all companies at Tables for discussion and potential Company lab tours arranged one on one.
Valley Research Park is a coworking research campus of 104,000 square feet hosting 30+ life science and technology companies. VRP has over 100 dry labs, wet labs, and high power labs sized from 300-3,000 square feet. Valley Research Park provides research companies a home base to research and develop their science. VRP offers terms that are flexible enough for them to conserve their capital without having to jump into a multi-year lease before they are ready.
R42
R42 was established out of Dr. Ronjon Nag's Family Office. Dr. Ronjon Nag is a seasoned entrepreneur and AI pioneer who cofounded and advised companies that were sold to Motorola, BlackBerry and Apple. With his family office and his high powered team of seasoned scientific advisors, R42 invests as an LP in funds as well as directly in companies to supercharge their growth. www.r42group.com/about
Companies Pitching:
NeuCyte
NeuCyte is a biotechnology company that focuses on developing treatments for those suffering from neurological and neurodegenerative disorders. NeuCyte develops translatable cell-based assays for modeling CNS-related disorders using patient-derived and genetically engineered neural cell types to discover novel therapeutics. Based on the SynFire® technology that includes proprietary human neural in vitro platforms, cell autonomous and non-cell autonomous phenotypes such as electrophysiological and morphological assays have been developed for target identification and validation, as well as drug efficacy testing. NeuCyte is actively pursuing drug discovery programs on Alzheimer's disease, ALS/FTD, Autism, and Epilepsy.
Yuvan Research Inc. is a longevity biotechnology company. Our lead therapeutic E5 has completed 4 successful preclinical trials in naturally old rats reversing than 30 age related biomarkers and two biological age clocks by 50%. We are now launching veterinary clinical trial in old Beagle dogs to make them systemically younger. Our first target is chronic kidney disease to be followed by fatty liver disease and chronic obstructive pulmonary disease.
Yuvan Research
Acoustic Bio
Acoustic Bio is an early-stage life sciences tools company that has developed an organoid-on-a-chip screening platform combined with AI-powered machine vision to provide an automated and scalable solution for personalized drug development, matching patients with drugs that will help them. Our innovative platform integrates microfluidics, live imaging, acoustic technology, and machine vision to deliver a first-in-class high-throughput organoid-on-a-chip screening platform. Our platform addresses the needs in assay throughput, speed, reproducibility, and automation to screen patient-derived organoids in preclinical drug development and, ultimately, in clinical settings.
Probius
Probius is a deep-tech company bridging the data gap between biology and Al. We are paving the way for a new age of biomedical research by taking advantage of the synergies between physics, mathematics, and biology.
Built on ten years of R&D, our proprietary Quantum Electrochemical Spectroscopy (QES) technology captures the unique composition of a biological specimen, measuring the vibrational frequencies of the molecules therein. QES then represents this multidimensional biological information as a digital twin in the cloud. This unbiased approach expedites data mining and discovery, as there is no need to rerun samples for further insight once the sample data is collected. The ability to dynamically analyze and quantify the samples' makeup, whether metabolites, proteins, or single-cell organisms, can be applied to different sample types and applications.
With an initial focus on preclinical applications, biomanufacturing, and translational research, we aim to enable an Al-driven approach to biomarker discovery and drug development. Over time, this new paradigm will fuel a decentralized model of predictive healthcare.
Info@probius.bio
Swaza
Swaza is developing the first nanofluid formulation to deliver oxygen to patients suffering oxygen loss.6 million global deaths from COVID19 exposed a shocking truth: There are no simple, effective treatments for critically low blood oxygen. Our vision is to create a breathing solution that's affordable, accessible, and easy to use, and that could be quickly deployed to combat acute oxygen loss worldwide.
Superbio
The world’s first ML store for biology
Gtcardio
At GTcardio our goal is to provide every person with the knowledge of their cardiovascular health every second of their life.
We are focused on developing technologies to optimize total wellbeing, improve longevity and prevent cardiovascular diseases. We do it by solving the problem of hypertension, by continuous hemodynamic monitoring, and assessing for personalized and optimal treatment to reduce vascular age.
AbTherx is advancing medicine with innovative technologies that accelerate and enable therapeutic antibody discovery. AbTherx’s Atlas™ Mouse platform provides the means to develop a clinically validated bispecific antibody format most similar to native antibodies and uses natural mechanisms to generate long CDR3 antibodies to improve the chance of success against challenging drug targets such as GPCRs and ion channels. Additionally, AbTherx is increasing access to transgenic mice expressing full human antibody diversity. Through technology licensing and research collaborations, AbTherx empowers drug developers of all sizes to overcome the most demanding challenges in delivering innovative medicines.
AbTherx
Base5 Genomics
https://www.b5genomics.com